Tumor necrosis factor receptor superfamily member 17 ( TNFRSF17 ), also known as B cell maturation antigen ( BCMA ) or CD269 antigen, is one of the members of the tumor necrosis factor receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes and is involved in B cell development and autoimmune response. This receptor has been shown to specifically bind to tumor necrosis factor (ligand) superfamily member 13 B (TNFSF13BABAF F), and cause NF-kappaB and MAPK8/JNK activation. BCMA also binds to different members of the TRAF family to mediate the transmission of cell survival and proliferation signals, so it can be used as a molecular target for drug development for certain immunodeficiency or autoimmune diseases. In BCMA as a target CAR-T has been in clinical trials for multiple myeloma. This product is a BCMA-FC recombinant protein, which can be used for monoclonal antibody screening or antibody function verification.

Product name: Recombinant human BCMA protein

Species: Human origin

Gene sequence number: NP_001183.2

Tags: Human-Fc Tag

Tag site: C terminal

Restriction site: none

Expression area: extracellular segment (1-54AA)

Host cell: 293F

Purity:> 90%

Purification method: Protein A column

Preservation system: PBS+20% glycerol

Storage conditions: -80℃

Illustration: Lane M on the left is protein MW marker, Lane 1 is 10ug BCMA-Fc protein;

The image on the right shows the FACS detection of the binding of BCMA protein to 293T overexpressing anti-BCMA-CAR.

Reference materials:

1. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity

2. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

3. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase